Published May 8, 2023
| Version v1
Publication
IgM-enriched immunoglobulin improves colistin efficacy in a pneumonia model by Pseudomonas aeruginosa
Description
We evaluated the efficacy of ceftazidime or colistin in combi nation with polyclonal IgM-enriched immunoglobulin (IgM-IG), in
an experimental pneumonia model (C57BL/6J male mice) using
two multidrug-resistant Pseudomonas aeruginosa strains, both
ceftazidime-susceptible and one colistin-resistant. Pharmaco dynamically optimised antimicrobials were administered for 72 h,
and intravenous IgM-IG was given as a single dose. Bacterial
tissues count and the mortality were analysed. Ceftazidime was
more effective than colistin for both strains. In mice infected with
the colistin-susceptible strain, ceftazidime reduced the bacterial
concentration in the lungs and blood (22.42 and 23.87 log10 CFU/
ml) compared with colistin (20.55 and 21.23 log10 CFU/ml, re spectively) and with the controls. Colistin plus IgM-IG reduced the
bacterial lung concentrations of both colistin-susceptible and
resistant strains (22.91 and 21.73 log10 CFU/g, respectively) and
the bacteraemia rate of the colistin-resistant strain (244%).
These results suggest that IgM-IG might be useful as an adjuvant
to colistin in the treatment of pneumonia caused by multidrug resistant P. aeruginosa.
Additional details
Identifiers
- URL
- https://idus.us.es/handle//11441/145619
- URN
- urn:oai:idus.us.es:11441/145619